Royalty Pharma Q1 2023 Earnings Report

Royalty Pharma EPS Results

• Actual EPS: $1.60
• Consensus EPS: $1.32
• Beat/Miss: Beat by +$0.28
• One Year Ago EPS: N/A

Royalty Pharma Revenue Results

• Actual Revenue: $1.13 billion
• Expected Revenue: $914.72 million
• Beat/Miss: Beat by +$216.28 million
• YoY Revenue Growth: N/A

Royalty Pharma Announcement Details

• Quarter: Q1 2023
• Date: 5/9/2023
• Time: N/A

Royalty Pharma (NASDAQ:RPRX) operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.